HROW250417P43000
- 14.50
- 0.000.00%
Harrow Newsroom
Taaleem to Launch Second Harrow International School in Dubai
AI replacing animal experiments? A message from the FDA has left "monkey breeders" feeling devastated, and experts state that "we are still far from the stage of implementation."
① The news that the USA FDA has publicly stated it will gradually replace animal testing requirements has led to an increase in the stock prices of AI pharmaceutical companies, impacting traditional drug evaluation CRO companies; ② Some believe this action represents a trend in Industry development. However, others believe that it is far from being implementable.
Express News | Harrow Inc - Klarity-C Patients to Access Vevye for $59 per Bottle
B.Riley Financial Maintains Harrow(HROW.US) With Buy Rating, Cuts Target Price to $65
Harrow Is Maintained at Buy by B. Riley Securities
Harrow Price Target Cut to $65.00/Share From $69.00 by B. Riley Securities
H.C. Wainwright Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $57
Express News | HC Wainwright & Co. Reiterates Buy on Harrow, Maintains $57 Price Target
Harrow Analyst Ratings
Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives
Harrow Health Reports Strong 2024 Financial Performance
Harrow Health (HROW) Gets a Buy From Craig-Hallum
Express News | Harrow Inc Shares up 7.7% at $30.02 After the Bell Following Results
Express News | Corrected-Harrow Inc: Q4 Core EPS $0.40 (Adds Dropped Word 'core')
10-K: FY2024 Annual Report
Harrow Q4 2024 Adj. EPS $0.40 Beats $0.07 Estimate, Sales $66.800M Beat $61.790M Estimate
8-K: Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results
Express News | Harrow Health Q4 Core Gross Margin 84%
Express News | Harrow Health Q4 Revenue USD 66.8 Million Vs. IBES Estimate USD 61.8 Million
Harrow 4Q EPS 24c >HROW